Company Overview and News

0
Knowing Futures and Options-I

7h freepressjournal.in
Futures and Options (F&O) is a relatively late entrant to the Indian market. Prior to that, speculative transactions used to be carried out under a system called ‘Badla’ – the Badla system was inefficient in as much as fraudsters could easily manipulate it to defraud and cheat investors. F&O is a refined, more efficient medium of speculation. Since the subject matter is complex, we intend to carry it over three parts.
OPTI

0
Knowing Futures and Options-I

2018-07-16 freepressjournal.in
Futures and Options (F&O) is a relatively late entrant to the Indian market. Prior to that, speculative transactions used to be carried out under a system called ‘Badla’ – the Badla system was inefficient in as much as fraudsters could easily manipulate it to defraud and cheat investors. F&O is a refined, more efficient medium of speculation. Since the subject matter is complex, we intend to carry it over three parts.
OPTI

0
Canadian Metals Inc. Appointments Patsie Ducharme Senior Vice President Finance and Chief Financial Officer

2018-06-28 globenewswire
MONTREAL, June 28, 2018 (GLOBE NEWSWIRE) -- Canadian Metals Inc. (The “Corporation”) (CSE:CME) is pleased to announce the appointment of Patsie Ducharme CPA as Senior Vice President Finance & Chief Financial Officer to replace Pierre Monet effective July 1, 2018.
TMBCF OPTI

0
Bank Nifty Calls see uptick in demand

2018-06-20 thehindubusinessline
Bank Nifty index declined on Tuesday taking cues from weak Asian and European markets. Bank Nifty Futures June contract was down by 125.45 points to end at 2,6260.80. The contract is trading at a 5-point discount to its underlying Bank Nifty index.
OPTI

0
Subdued trade movement seen in Bank Nifty calls

2018-06-07 thehindubusinessline
The Bank Nifty index ended higher on Wednesday shrugging off the rate hike by the RBI. The markets have discounted the rate hike, it seems. The Bank Nifty Futures June contract was up by 125 points on Wednesday and closed at 26383 levels. The contract is trading at a premium of 16 points to its underlying Bank Nifty index.
OPTI

0
Open interest seen cutting across bank Nifty put options

2018-05-30 thehindubusinessline
The Bank Nifty Futures May contract fell by 374 points on Tuesday and closed at 26,167 levels. The contract is trading at a discount to its underlying Bank Nifty index, which fell about 359 points to close at 26,254. The sectoral indices related to Bank Nifty also showed a negative trend. The Nifty PSU Bank index fell 89 points or 2.95 per cent to end at 2,940 levels, while the Nifty PVT Bank index also slipped 200 points or 1.
FORTIS 532843 OPTI

239
Pay-to-Use Facebook, Inc.? The Option’s Likely Coming, But…

2018-04-11 investorplace
As expected, the Congressional grilling of Facebook, Inc. (NASDAQ:FB) CEO Mark Zuckerberg was quite the spectacle. And, given the 4.5% rebound FB stock dished out following Tuesday’s meeting, investors clearly felt Zuck won whatever game was being played in Washington, D.C.
FB AMZN TWTR NFLX SNAP OPTI

28
DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

2018-03-21 globenewswire
DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
DBV MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA BR OPTI

0
CordovaCann Signs Exclusive Option to Enter California Cannabis Market

2018-03-13 accesswire
TORONTO, ON / ACCESSWIRE / March 13, 2018 / CordovaCann Corp. (OTCQB: LVRLF) ("CordovaCann" or the "Company") announced today that the Company has entered into a memorandum of understanding (the "MOU") with Humboldt Healthcare, LLC ("Humboldt Healthcare") to grant the Company an exclusive option (the "Option") to acquire a majority stake in real estate and intellectual property assets owned by Humboldt Healthcare that serve California's recreational marijuana sector (collectively, the "Assets").
LVRLF OPTI

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EBR:OPTI / OPTION on message board site Silicon Investor.

NexOptic Technology Corp Optical Networks and Components, DWDM and Tunable Lasers
Option Strategies Options Investing: Trading the FTSE 100 and UK Stock Benchma
Gigoptix, Inc. Illumina (ILMN) Optics for Genomics
OPTI Broadband u0026 Fiber-Optic Companies to invest in.
Search Engines - options and opinions - Ask, Bing, Google, Binary Options Brokers - So Many To Choose, So Little Are Le